Ketanserin: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{drugbox | {{drugbox | ||
| IUPAC_name = | | IUPAC_name = | ||
| Line 26: | Line 25: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 39: | Line 38: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
{{Antihypertensives and diuretics}} | {{Antihypertensives and diuretics}} | ||
[[Category: | [[Category:Antihypertensive agents]] | ||
[[Category:Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
[[ | |||
Revision as of 00:31, 25 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22FN3O3 |
| Molar mass | 395.43 g/mol |
|
WikiDoc Resources for Ketanserin |
|
Articles |
|---|
|
Most recent articles on Ketanserin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ketanserin at Clinical Trials.gov Clinical Trials on Ketanserin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ketanserin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ketanserin Discussion groups on Ketanserin Patient Handouts on Ketanserin Directions to Hospitals Treating Ketanserin Risk calculators and risk factors for Ketanserin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ketanserin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ketanserin is a serotonin receptor antagonist. It has the highest affinity for the serotonin 5-HT2A receptor, but also binds less potently to the 5-HT2C, 5-HT2B, 5-HT1D, alpha-adrenergic, and dopamine receptors. With tritium radioactively labeled ketanserin is used as a radioligand for the serotonin 5-HT2A receptor, e.g. in receptor binding assays.
Ketanserin was discovered at Janssen Pharmaceutica in 1980.
It is classified as an antihypertensive by the World Health Organization[1] and the National Institute of Health.[2]
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antihypertensive agents
- Cardiovascular Drugs
- Drug